For reasons that are not readily apparent, BCL6 is the most common non-IgV target of SHM52,53, with 59–73% of DLBCL cases55,57 and even ~30% of normal GC B-cells57 showing evidence of SHM in the 5′ noncoding region. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.